Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database
Open Access
- 3 June 2010
- Vol. 15 (6), 4041-4054
- https://doi.org/10.3390/molecules15064041
Abstract
Epidermal growth factor receptor (EGFR) abnormalities have been associated with several types of human cancer. The crystal structures of its tyrosine kinase domain (EGFR-TK) complexed with small molecule inhibitors revealed the kinase inhibition modes, prompting us to search for novel anti-cancer drugs. A total of 1,990 compounds from the National Cancer Institute (NCI) diversity set with nonredundant structures have been tested to inhibit cancer cell lines with unknown mechanism. Cancer inhibition through EGFR-TK is one of the mechanisms of these compounds. In this work, we performed receptor-based virtual screening against the NCI diversity database. Using two different docking algorithms, AutoDock and Gold, combined with subsequent post-docking analyses, we found eight candidate compounds with high scoring functions that all bind to the ATP-competitive site of the kinase. None of these compounds belongs to the main group of the currently known EGFR-TK inhibitors. Binding mode analyses revealed that the way these compounds complexed with EGFR-TK differs from quinazoline inhibitor binding and the interaction mainly involves hydrophobic interactions. Also, the common kinase-inhibitor (NH---N and CO---HC) hydrogen bonds between the hinge region and the hit compounds are rarely observed. Our results suggest that these molecules could be developed as novel lead compounds in anti-cancer drug design.Keywords
This publication has 45 references indexed in Scilit:
- Quantitative Prediction of Fold Resistance for Inhibitors of EGFRBiochemistry, 2009
- Protein kinase inhibitors: contributions from structure to clinical compoundsQuarterly Reviews of Biophysics, 2009
- Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interfaceNature, 2007
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2005
- Novel technologies for virtual screeningDrug Discovery Today, 2004
- Improved protein–ligand docking using GOLDProteins-Structure Function and Bioinformatics, 2003
- The discovery of steroids and other novel FKBP inhibitors using a molecular docking programJournal of Molecular Biology, 1999